ReNeuron set to raise GBP3M via share placing
UK stem cell specialist ReNeuron intends to raise up to GBP3.0 million ($4.6 million) via a placing of up to 10 million new ordinary shares of 1 pence each credited as fully paid up at a price of 3 pence each.
The company has subsequently announced three successive closings of the placing, with the issue and allotment of 66,211,111 ordinary shares in aggregate as a result.
On May 18, ReNeuron announced that a further 33,722,223 ordinary shares have been allotted and issued at fourth and final closing of the placing, bringing the aggregate gross proceeds to the full GBP3.0 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze